FORMULATION ARTICLES
-
![GettyImages-2284767177.jpg]( "Beyond Better Models: Why The Future Of AI-Designed mRNA Depends On More Relevant Biological Data")
Beyond Better Models: Why The Future Of AI-Designed mRNA Depends On More Relevant Biological DataAI can optimize mRNA only if it's trained on biologically relevant data. Better therapeutic datasets — not just better algorithms — will drive the next generation of RNA medicines.
-
![GettyImages-1494348289_lab microscope]( "The Delivery Challenge For In Vivo Cell Engineering")
The Delivery Challenge For In Vivo Cell EngineeringAs RNA therapies expand beyond the liver, delivery—not payload design—has become the defining challenge for precise, scalable in vivo cell engineering.
-
![GettyImages-480155972_Leukodystrophy]( "Building An ASO For TUBB4A-Related Leukodystrophy (Pt. 1)")
Building An ASO For TUBB4A-Related Leukodystrophy (Pt. 1)SynaptixBio CEO Dan Williams explains how the company selected an ASO for TUBB4A leukodystrophy by balancing potency, safety, and translational rigor to advance a rare disease therapy.
-
![double stranded circular rna-GettyImages-2220593312]( "Location Matters: How The Nuclear Geography Of circRNAs Could Shape The Future Of RNA Therapeutics")
Location Matters: How The Nuclear Geography Of circRNAs Could Shape The Future Of RNA TherapeuticsCircRNA location may be as important as its sequence. Discover how nuclear organization could influence the next generation of RNA therapeutics.
-
![drug delivery, nanotechnology technology-GettyImages-1337413453]( "Building The RNA Knowledge Graph: How Better Annotation Is Accelerating Therapeutic Discovery")
Building The RNA Knowledge Graph: How Better Annotation Is Accelerating Therapeutic DiscoveryAs RNA therapeutics grow more complex, better biological annotation is becoming the foundation for AI-driven discovery, target selection, and smarter drug development.
-
![Small interfering RNA, sirna, mrna, crispr-GettyImages-1409578453]( "Building A Self-Driving Lab For LNP Development")
Building A Self-Driving Lab For LNP DevelopmentWith commercially available components, MIT researchers built a platform that accelerates LNP process development, optimization, and autonomous manufacturing research.
FORMULATION VIDEOS
Review strategies to assess the potential for human immune response following the administration of an mRNA therapeutic, the associated LNP, and the protein encoded for by the mRNA.
Dr. Michael Buschmann, George Mason University, presents an overview of molecular and colloidal ionization properties of lipid nanoparticle mRNA vaccines.
The clinical promise of mRNA therapeutics and vaccines is clear, but compared to monoclonal antibodies or viral vectors, their novelty also brings new challenges to the manufacturing process.
Dr. Gerrit Borchard, University of Geneva, presents a personal account of DNA vaccine development in a global pandemic.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![mRNA GettyImages-1428646288]( "Establishing Analytical Methods For mRNA-Based Therapies")
Here, we provide a detailed description of assays for sequence identification and LNP composition in mRNA-LNP products that support the development of safe and effective mRNA therapies.
-
![GettyImages-1622519985 cryopreservation, cold chain]( "Standardization Where It Matters Most")
Freezing doesn’t ensure consistency. Standardized cryopreservation removes site‑to‑site variability, providing predictable starting materials and lowering scientific and operational risk.
-
![MRNA Technology-GettyImages-1366661187]( "Developing An mRNA-Encoded Antibody Platform To Accelerate Therapies To Clinic")
In this paper, we present the foundation of an mRNA-LNP platform for encoding and expressing therapeutic antibodies in vivo, eliminating the need for costly and time-consuming manufacturing.
-
![GettyImages-1695276785 lab, vial, research]( "Comparing Microfluidic Mixing With A Turbulent Jet Approach For Lipid Nanoparticles")
A comparative study examines how two mixing technologies, microfluidic and turbulent jet, influence the attributes of lipid nanoparticles and their suitability for different stages of drug development.
-
![Doctor Preparing Injection Site GettyImages-1379313214]( "How LNP Technology Meets The Delivery Need Of saRNA Vaccines")
Explore challenges to the successful development of RNA-based drugs and vaccines as well as the advantages of utilizing lipid nanoparticle technology as a delivery platform for saRNA.
-
![GettyImages-1437856375-lnp-lipid-nanoparticle]( "Regulatory Considerations For Excipients Used In Lipid Nanoparticles")
Review the regulatory classification of LNPs, liposomes, and novel excipients as well as specific requirements outlined in regulatory guidance documents and strategies to navigate emerging challenges.
-
![GettyImages-1087219020 Scientists wearing protective coveralls working in manufacturing laboratory]( "Insights Into GMP Manufacturing Of RNA-LNP Drug Products")
Explore key considerations for manufacturing RNA-LNP drug products surrounding process and analytical development, automation, environmental monitoring, and strategic collaborations.
